A recent study reported that HTR1A inhibited the progression of triple-negative breast cancer via TGF-β canonical and noncanonical pathways and HTR1A agonists significantly improved patient survival (31). This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.